Both Sides of the Table

JUNE 3, 2010

I don’t do advertising on my blog, but I thought it was worth mentioning Ryan in particular because he has an alternate model for doing a startup. Pricing engine helps publishers ascertain ad inventory pricing by analyzing ad transaction data from the market/exchanges. They sponsor TWiVC. MetaMarkets. Hello, Chair.

Venture Capital 214

Venture Capital Startup Design S3 214

Both Sides of the Table

JUNE 18, 2010

An investment doesn’t guarantee your product will suddenly be on the investor’s price sheet. Diverse search results include stream updates, blog posts, news articles, photos, videos (versus Twitter/FaceBook1 only). Current round: $5.0mm in Series A by NEA and Anthem Venture Partners. Real-time search engine.

Venture Capital 225

Venture Capital Google Web Sites 225

Xconomy

JANUARY 24, 2017

One of the nation’s major health insurers has placed limitations on access to the first-ever approved drug for the rare spinal muscular atrophy, validating patient fears that the high price tag of the drug, nusinersen (Spinraza), might make it hard for some with the disease to get treatment.

Anthem 40

Anthem Pricing San Diego Blogging 40

Xconomy

FEBRUARY 2, 2017

health insurer, UnitedHealthCare, has said it would cover the first-ever approved drug for the rare disease spinal muscular atrophy, a closely watched bellwether in the national debate over drug prices. Another major U.S.

Anthem 40

Anthem Pricing San Diego Blogging 40

Xconomy

JANUARY 6, 2017

But just after Christmas, she saw the price. More than a decade after his diagnosis, Mikhail only has the strength to take a few steps on his own. With the approval, Memedovich finally had hope. Cambridge, MA-based Biogen (NASDAQ: BIIB ), the drug’s. Read more » Reprints | Share:

Pricing 78

Pricing Anthem San Diego Blogging 78

Xconomy

APRIL 20, 2017

Melissa Marotta pulled no punches to get her three-year-old son C.J., who has the genetic disease spinal muscular atrophy, access to nusinersen (Spinraza), the first approved drug for his condition.

Anthem 73

Anthem San Diego Pricing Blogging 73

Xconomy

FEBRUARY 3, 2017

At the same time, a handful of the industry’s top CEO’s flew to Washington for a meeting with the President, who promised to speed the drug approval process, lower drug prices, and overhaul the FDA. Meanwhile, the future of the Affordable Care Act remains undecided, and Tom Price’s controversial candidacy for the top healthcare.

Pricing 40

Pricing Anthem San Diego Blogging 40